TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock Has Average Price Target of $2.67

TScan Therapeutics, Inc. (NASDAQ:TCRX) has earned an average rating of “Hold” from the eight research firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $2.67.

A number of research analysts have weighed in on the stock. Benchmark reaffirmed a “buy” rating on shares of TScan Therapeutics in a research note on Thursday, August 13th. Lifesci Capital downgraded shares of TScan Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 2nd. HC Wainwright downgraded shares of TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 target price for the company. in a research report on Tuesday, September 8th. Weiss Ratings lowered shares of TScan Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 8th. Finally, Wedbush cut shares of TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 price target on the stock. in a research report on Wednesday, September 2nd.

TScan Therapeutics Trading Up 2.7%

Shares of TScan Therapeutics stock opened at $0.18 on Tuesday. The stock has a market capitalization of $12.15 million, a PE ratio of -0.20 and a beta of 1.15. TScan Therapeutics has a 52 week low of $0.17 and a 52 week high of $1.48. The stock has a 50 day moving average price of $0.35 and a two-hundred day moving average price of $0.85. The company has a debt-to-equity ratio of 0.31, a quick ratio of 3.37 and a current ratio of 3.37.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Wednesday, August 12th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. TScan Therapeutics had a negative return on equity of 108.72% and a negative net margin of 1,655.35%. The company had revenue of $1.05 million for the quarter, compared to analyst estimates of $1.88 million. As a group, equities analysts anticipate that TScan Therapeutics will post -0.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Renaissance Technologies LLC lifted its stake in TScan Therapeutics by 19.6% during the 1st quarter. Renaissance Technologies LLC now owns 1,364,783 shares of the company’s stock valued at $1,378,000 after acquiring an additional 223,714 shares in the last quarter. BlackRock Inc. bought a new position in shares of TScan Therapeutics during the second quarter valued at about $975,000. GSA Capital Partners LLP purchased a new position in TScan Therapeutics during the second quarter worth about $537,000. NewEdge Wealth LLC purchased a new position in TScan Therapeutics during the second quarter worth about $90,000. Finally, Kestra Advisory Services LLC purchased a new position in TScan Therapeutics during the first quarter worth about $63,000. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer. Its approach involves genetically modifying a patient’s T cells to recognize specific cancer-related antigens, with the goal of directing the immune system to attack malignant cells.

The company’s pipeline includes investigational therapies for hematologic malignancies and solid tumors. Its lead programs, TSC-100 and TSC-101, are designed to target the HA-1 antigen in patients with certain blood cancers following an allogeneic hematopoietic stem cell transplant.